Examination of the Impact of CYP3A4/5 on Drug–Drug Interaction between Schizandrol A/Schizandrol B and Tacrolimus (FK-506): A Physiologically Based Pharmacokinetic Modeling Approach

Qingfeng He 1,†, Fengjiao Bu 1,†, Qizhen Wang 1, Min Li 1, Jiaying Lin 1, Zhijia Tang 1○, Wen Yao Mak 1,2,3 ○, Xiaomei Zhuang 4, Xiao Zhu 1, Hai-Shu Lin 5,*, and Xiaoqiang Xiang 1,*,†

1. Introduction

Pharmacokinetic drug interaction can occur when one drug affects the absorption, distribution, metabolism, or excretion (ADME) of another drug [1]. The complexity of ADME processes is attributed to numerous functional proteins with individual variations. Since many therapeutic agents undergo metabolism by cytochrome P450 (CYP) 3A enzymes, the metabolic inhibition and induction can result in drug–drug interaction (DDI) that can lead to unexpected therapeutic effects or adverse drug reactions. In recent years, there has been increasing interest in the use of traditional Chinese medicine (TCM) in Western countries, especially during the COVID-19 pandemic. Some clinical reports have suggested that the coadministration of conventional (Western) medicine with TCM can alter the pharmacokinetics of the conventional medicine due to DDI. Therefore, it is crucial to understand the mechanisms underlying these interactions to ensure the safe and effective use of these combined therapies.

In this study, we investigated the impact of Schizandrol A (SZA) and schizandrol B (SZB) on the pharmacokinetics of tacrolimus (FK-506), a commonly prescribed immunosuppressant. Schizandrol A and schizandrol B are two active ingredients of Wuzhi capsule (WZC), a Chinese proprietary medicine commonly prescribed to alleviate tacrolimus (FK-506)-induced hepatoxicity in China. Due to their inhibitory effects on cytochrome P450 (CYP) 3A enzymes, SZA/SZB may display drug–drug interaction (DDI) with tacrolimus. To identify the extent of this DDI, the enzymes' inhibitory profiles, including a 50% inhibitory concentration (IC50) shift, reversible inhibition (RI) and time-dependent inhibition (TDI) were examined with pooled human-liver microsomes (HLMs) and CYP3A5-genotyped HLMs. Subsequently, the acquired parameters were integrated into a physiologically based pharmacokinetic (PBPK) model to quantify the interactions between the SZA/SZB and the tacrolimus. The metabolic studies indicated that the SZB displayed both RI and TDI on CYP3A4 and CYP3A5, while the SZA only exhibited TDI on CYP3A4 to a limited extent. Moreover, our PBPK model predicted that multiple doses of SZB would increase tacrolimus exposure by 26% and 57% in CYP3A5 expressers and non-expressers, respectively. Clearly, PBPK modeling has emerged as a powerful approach to examine herb-involved DDI, and special attention should be paid to the combined use of WZC and tacrolimus in clinical practice.

Keywords: physiologically based pharmacokinetic (PBPK); Wuzhi capsule (WZC); tacrolimus (FK-506); CYP3A5 polymorphism; drug–drug interaction (DDI); schizandrol A (SZA); schizandrol B (SZB)
Some clinical reports have suggested that the coadministration of conventional (Western) medicine with TCM could reduce toxicity and/or enhance therapeutic efficacy [4,5]. However, TCM products could cause DDI and affect the metabolism and clearance of various drugs via CYP450 inhibition [6]. The composition of TCM preparations is complicated by the uncertain contents of bioactive ingredients, which fluctuate wildly due to the varied growing origins and culturing techniques. The lack of consistency and standardization makes it difficult to evaluate the DDIs between TCM and Western medicine in clinical settings. As conventional medicine is commonly used together with TCM in China, there is an urgent need to appraise the safety and effectiveness of this integrative practice.

Wuzhi capsule (WZC) is an ethanol extract of the Schisandra sphenanthera with major bioactive chemical components including schisantherin A (STA), schisandrin A (SIA), schizandrol A (SZA) and schizandrol B (SZB). Since WZC alleviates drug-induced liver toxicity and damage, it is commonly co-prescribed with hepatotoxic drugs in China [7]. Tacrolimus (FK-506), a first-line immunosuppressive agent indicated for solid-organ transplantation, is mainly metabolized by CYP3A4 and CYP3A5 and eliminated in the liver [8–10]. Due to its narrow therapeutic index and pharmacokinetic variations, patients with different pathophysiological conditions are prone to suffer from overexposure or underexposure [11]. The coadministration of CYP3A inhibitor can increase tacrolimus’s blood concentration, resulting in nephrotoxicity and a higher infection risk. Although commonly prescribed together with tacrolimus, WZC significantly increased the whole blood concentration of tacrolimus [12,13]. Mechanistic studies further revealed the inhibitory potency of STA and SIA, active constituents of Schisandra sphenanthera, on CYP3A4 and CYP3A5 [1,14–17]. Similarly, SZA and SZB (structures displayed in Figure 1) also affected CYP3A enzymes, and the systemic exposure of tacrolimus was increased by 598.4% in rats after the oral administration of SZB [16].
 served in CYP3A5 expressers of CYP3A5* 1 allele (active genotype) in comparison to CYP3A5* 3 alleles (inactive genotype) [21]. Therefore, dose adjustment is recommended by the Clinical Pharmacogenetics Implementation Consortium (CPIC), while CYP3A5* 1 allele carriers should receive 1.5 to 2 times higher doses of tacrolimus to achieve blood exposure similar to CYP3A5 non-expressers [18].

Physiologically based pharmacokinetic (PBPK) modeling has been used to predict concentration-time profiles and, therefore, adapted in DDI investigations [22–25]. When dealing with herbal medicines/natural products, PBPK modeling applies in vitro to in vivo extrapolation and predicts pharmacokinetic drug interactions and toxicological profiles in a simulation manner [22,26]. We successfully quantified the contribution of STA and SIA to the DDI between tacrolimus and WZC in previous studies [14,17]. However, the impact of the pharmacogenetic polymorphism of CYP3A5 on the interaction between tacrolimus and SZA/SZB remains largely unclear. In this study, we first assessed the inhibitory potencies of SZA and SZB on CYP3A4/5 and then examined the contribution of CYP3A5 polymorphism to the variability of the interaction between tacrolimus and WZC by constructing a PBPK–DDI model integrated with pharmacogenomic factor as a quantitative parameter. Hopefully, the information obtained in this study will improve our understanding of the DDI between WZC and tacrolimus and enhance their clinical safety and effectiveness.

2. Results

2.1. IC_{50} Shift

The IC_{50} values of SZA (63.46 µM for no preincubation, 40.45 µM for preincubation with NADPH) and SZB (11.98 M for no preincubation, 0.56 µM for preincubation with NADPH) are shown in Figure 1. The IC_{50} shift values were calculated to be 1.57 for SZA and 21.39 for SZB.

2.2. RI Assay

Dixon plots were used to yield the K_i values for the inhibition by SZA or SZB. The reaction rate did not change significantly as the SZA’s concentration increased in the incubation with the pooled HLMs (Figure 2A), demonstrating little reversible inhibition on CYP3A by SZA. However, as shown in Figure 2B, the SZB presented a competitive and reversible inhibition pattern with a K_i value of 5.82 µM. A further evaluation of the inhibitory pattern of SZB on CYP3A4 and CYP3A5 with different genotyped HLMs was performed, and the values of K_i (2.18 and 2.03 µM, respectively) are displayed in Figure 2C,D.

2.3. TDI Assay

The formation of 6β-hydroxytestosterone was used to measure the enzymatic activity of CYP3A4 and 3A5. As presented in Figure 3, both the SZA and the SZB exhibited a powerful TDI on the CYP3A. The k_{inact} and K_i values of the SZA on the CYP3A were 0.029 min^{-1} and 15.625 µM, respectively, compared with 0.044 min^{-1} and 0.43 µM for SZB. Further investigation on the CYP3A4 and CYP3A5 separately indicated that the SZA had a slight TDI on the CYP3A4 (k_{inact} = 0.024 min^{-1}, K_i = 15.38 µM) but not on the CYP3A5 (Figure 4). The SZB demonstrated a strong irreversible inhibition on both the CYP3A4 (k_{inact} = 0.37 min^{-1}, K_i = 0.69 µM) and the CYP3A5 (k_{inact} = 0.009 min^{-1}, K_i = 0.5 µM) (Figure 5).
2.3. TDI Assay

The formation of 6β-hydroxytestosterone was used to measure the enzymatic activity of CYP3A4 and 3A5. As presented in Figure 3, both the SZA and the SZB exhibited a powerful TDI on the CYP3A. The kinact and KI values of the SZA on the CYP3A were 0.029 min⁻¹ and 15.625 μM, respectively, compared with 0.044 min⁻¹ and 0.43 μM for SZB. Further investigation on the CYP3A4 and CYP3A5 separately indicated that the SZA had a slight TDI on the CYP3A4 (kinact = 0.024 min⁻¹, KI = 15.38 μM) but not on the CYP3A5 (Figure 4). The SZB demonstrated a strong irreversible inhibition on both the CYP3A4 (k inact = 0.37 min⁻¹, KI = 0.69 μM) and the CYP3A5 (kinact = 0.009 min⁻¹, KI = 0.5 μM) (Figure 5).

Figure 2. Dixon plots of SZA (A) and SZB (B) on tacrolimus metabolism mediated by CYP3A metabolism in pooled HLMs. Various concentrations of tacrolimus (0.25, 0.5, 1, 2 μM), SZA (0, 4, 8, 16 μM) and SZB (0, 1, 2, 4 μM) were used. Dixon plot of SZB on CYP3A4 (C) and CYP3A5 (D) in genotyped HLMs. Various concentrations of tacrolimus (0.5, 1, 2, 4 μM) and SZB (0, 1, 2, 4 μM) were used. Experiments were conducted in triplicates.

Figure 3. Dixon plots of SZA (A,B) and SZB (C,D) on CYP3A inactivation in pooled HLMs. Various concentrations of SZA (0, 10, 16, 20, 25, 32 μM) and SZB (0, 0.1, 0.2, 0.5, 1, 2 μM) were pre-incubated at 37 °C for 0, 5, 10, 20 and 30 min in 0.1 M PBS. (A,C) were plotted with the log of percentages of control activity versus preincubation time. (B,D) were plotted with the half-life of enzyme inactivation versus the inverse of the SZA or SZB concentration. Each point represents the mean of triplicate experiments.
Comparing the predicted data with the observed data, we reported that all of the fold error was calculated to measure the accuracy of the simulation, with values of less than 2 (Equation (1)).

\[
\text{Fold error} = \frac{\text{predicted value}}{\text{observed value}}
\]

The observed data were retrieved from the published literature to predict the plasma concentration-time profiles in vivo. The observed pharmacokinetic parameters in vivo were less than 2 (shown in Table 1), with good linearity (shown in Figure 6).

Various concentrations of SZB (0, 0.5, 1, 2, 4, 8 µM) were pre-incubated at 3 °C for 0, 5, 10, 20 and 30 min in 0.1 M PBS. (A) was plotted with the log of the percentage of control activity versus preincubation time. (B) was plotted with the half-life of enzyme inactivation versus the inverse of the SZB concentration. Each point represents the mean of triplicate experiments.

Various concentrations of SZA (0, 10, 16, 20, 25, 32 µM) were pre-incubated at 37 °C for 0, 5, 10, 20 and 30 min in 0.1 M PBS. (A) was plotted with the half-life of enzyme inactivation versus the inverse of the SZA concentration. Each point represents the mean of triplicate experiments.

Various concentrations of SZA (0, 10, 16, 20, 25, 32 µM) for CYP3A4 and 0, 10, 20, 30, 40, 50 µM for CYP3A5) were pre-incubated at 3 °C for 0, 5, 10, 20 and 30 min in 0.1 M PBS. (A,C) were plotted with the log of the percentage of control activity versus preincubation time. (B) was plotted with the half-life of enzyme inactivation versus the inverse of the SZA concentration. Each point represents the mean of triplicate experiments.

Various concentrations of SZB (0, 0.1, 0.2, 0.5, 1, 2 µM) for CYP3A4 and 0, 10, 20, 30, 40, 50 µM for CYP3A5) were pre-incubated at 37 °C for 0, 5, 10, 20 and 30 min in 0.1 M PBS. (A,D) were plotted with the log of the percentage of control activity versus preincubation time. (B,D) were plotted with the half-life of enzyme inactivation versus the inverse of the SZB concentration. Each point represents the mean of triplicate experiments.

Figure 4. Dixon plots of SZA on CYP3A4 (A,B) and CYP3A5 (C) inactivation in genotyped HLMs. Various concentrations of SZA (0, 10, 16, 20, 25, 32 µM for CYP3A4 and 0, 10, 20, 30, 40, 50 µM for CYP3A5) were pre-incubated at 3 °C for 0, 5, 10, 20 and 30 min in 0.1 M PBS. (A,C) were plotted with the log of the percentage of control activity versus preincubation time. (B) was plotted with the half-life of enzyme inactivation versus the inverse of the SZA concentration. Each point represents the mean of triplicate experiments.

Figure 5. Dixon plots of SZB on CYP3A4 (A,B) and CYP3A5 (C,D) inactivation in genotyped HLMs. Various concentrations of SZB (0, 0.5, 1, 2, 4, 8 µM for CYP3A4 and 0, 2, 4, 8, 16 µM for CYP3A5) were pre-incubated at 37 °C for 0, 5, 10, 20 and 30 min in 0.1 M PBS. (A,C) were plotted with the log of the percentage of control activity versus preincubation time. (B,D) were plotted with the half-life of enzyme inactivation versus the inverse of the SZB concentration. Each point represents the mean of triplicate experiments.
2.4. Model Establishment and Validation

2.4.1. PBPK Models for SZA and SZB

The observed data were retrieved from the published literature to predict the plasma concentrations of the SZA and the SZB after the oral administration of WZC in healthy Chinese populations [27]. Even though the amounts of the SZA and SZB in the WZC were small, the in vivo exposure was relatively large. Due to the difficulty of achieving the reported area under the curve (AUC) with the actual proportion of SZA and SZB, we used a virtual dose calculated by Simcyp® and established PBPK models for single doses of SZA (33.6 mg) and SZB (10.8 mg) in healthy volunteers. As shown in Equation (1), the fold error was calculated to measure the accuracy of the simulation, with values of less than 2 indicating a precise prediction.

\[
\text{Fold error} = \begin{cases} 
\frac{\text{predicted value}}{\text{observed value}} & \text{(if predicted > observed)} \\
\frac{\text{observed value}}{\text{predicted value}} & \text{(if observed > predicted)} 
\end{cases}
\]

Comparing the predicted data with the observed data, we reported that all of the fold error values for the pharmacokinetic parameters in vivo were less than 2 (shown in Table 1), with good linearity (shown in Figure 6).

| PK Parameters | SZA          | SZB          |  | Pre 1 | Obs 2 | FE 3 | Pre  | Obs | FE  |
|---------------|--------------|--------------|---|-------|------|------|------|-----|-----|
| C_{max}[^4]  | 126.88       | 111.37       | 1.14| 66.70 | 65.18| 1.02 |
| T_{max}[^3]  | 0.96         | 1.81         | 1.90| 0.73  | 1.13 | 1.54 |
| AUC (ng/mL·h)| 437.80       | 467.14       | 1.10| 271.74| 242.97| 1.12 |

[^1] Pre: predicted;[^2] Obs: observed;[^3] FE: fold error;[^4] C_{max}: total maximal concentration in plasma;[^5] T_{max}: the time after administration at which the plasma drug concentration reaches C_{max}.

Table 1. Predicted and observed values for pharmacokinetic parameters of SZA and SZB.

Figure 6. Simulation of plasma-concentration-time profiles of SZA (A) after a single oral dose of 33.6 mg and SZB (B) after a single oral dose of 10.8 mg in healthy Chinese patients generated by Simcyp®.

2.4.2. DDI Simulation Modeling

Based on the developed human PBPK models of tacrolimus, SZA and SZB, we integrated the acquired RI kinetic parameter (k_I), the TDI kinetic parameters (k_I and k_{max}) and the aforementioned kinetic parameters to form a DDI simulation model. Two sets of dosing protocols were created. In the first, the patients took a single dose of inhibitor (33.6 mg SZA or 10.8 mg SZB) with 2 mg tacrolimus; in the second, the patients received 16.8 mg of SZA or 5.4 mg of SZB twice daily for 13.5 days, followed by a single tacrolimus dose of 2 mg on day 14. Three different cases with different inhibition patterns were developed to
distinguish the contributions of the RI and TDI to the increase in tacrolimus AUC in the CYP3A5 expressers and non-expressers, respectively. Case #1 only includes the RI, #2 only covers the TDI and #3 combines both the RI and the TDI.

2.4.3. DDI Prediction in CYP3A5 Expressers

Under the conditions of case #3, the predicted AUC of the tacrolimus after a single oral dose of SZB was increased by 15% to 72.12 ng/mL·h, while multiple doses of SZB increased the AUC of tacrolimus by 23% to 76.68 ng/mL·h. In the single-dose simulation, the RI (case #1) and TDI (case #2) by SZB increased the AUC of the acrolimus by 12% and 4%, respectively, while 13% increases were noticed in both multiple-dose settings. However, the coadministration of SZA had little influence on the blood concentrations of tacrolimus in both single and multiple-dose settings.

2.4.4. DDI Prediction in CYP3A5 Non-Expressers

Under the conditions of case #3, the predicted AUC of the tacrolimus in the blood after a single oral dose of SZB was increased by 14% to 135.01 ng/mL·h, while multiple doses of SZB increased the AUC of the tacrolimus by 57% to 185.61 ng/mL·h. The RI and TDI by SZB in the single-dose simulation increased the AUC of the tacrolimus by 9% and 6%, respectively, compared to the 26% and 47% increases in the multidose setting. In the simulation with the SZA, only a small alteration in the AUC ratio (AUCR) via the TDI, with values of 1.10 and 1.16, was obtained between the single-dose and multiple-dose scenarios, respectively. The results are presented in Figures 7 and 8 and Table 2.

Figure 7. Change in tacrolimus exposure after a single dose of 33.6 mg SZA in CYP3A5 expressers (A) and CYP3A5 non-expressers (B); and after multiple doses of SZA (16.8 mg b.i.d. for 13.5 days) in CYP3A5 expressers (C) and CYP3A5 non-expressers (D).
the simulation with the SZA, only a small alteration in the AUC ratio (AUCR) via the TDI, with values of 1.10 and 1.16, was obtained between the single-dose and multiple-dose scenarios, respectively. The results are presented in Figures 7 and 8 and Table 2.

**Figure 7.** Change in tacrolimus exposure after a single dose of 33.6 mg SZA in CYP3A5 expressers (A) and CYP3A5 non-expressers (B); and after multiple doses of SZA (16.8 mg b.i.d. for 13.5 days) in CYP3A5 expressers (C) and CYP3A5 non-expressers (D).

**Figure 8.** Change in tacrolimus exposure after a single dose of 10.8 mg SZB in CYP3A5 expressers (A) and CYP3A5 non-expressers (B); and after multiple doses of SZB (5.4 mg b.i.d. for 13.5 days) in CYP3A5 expressers (C) and CYP3A5 non-expressers (D).

**Table 2.** Alterations in tacrolimus exposure after a single dose or multiple doses of SZA and SZB in CYP3A5 expressers and non-expressers.

| Population    | Inhibitors | Dose Regimen | RI Case#1 | TDI Case#2 | RI and TDI Case#3 |
|---------------|------------|--------------|-----------|------------|------------------|
| CYP3A5        |            |              |           |            |                  |
| Non-expresser | SZA        | Single dose  | —         | 118.07/118.17 | 1.00/1.00       |
|               |            | —            | —         | 118.07/136.76 | 1.16/1.16       |
|               |            | Multiple doses |          | 118.07/128.33 | 1.09/1.06       |
|               |            | Single dose  | 118.07/124.60 | 118.07/135.01 | 118.07/185.61 |
|               |            | Multiple doses |          | 118.07/148.65 | 1.26/1.47       |
|               | SZB        |              |           |            |                  |
| Expresser     |            |              |           |            |                  |
|               | SZA        | Single dose  | —         | 62.50/62.54  | 1.00/1.00       |
|               |            | —            | —         | 62.50/62.66  | 1.00/1.00       |
|               |            | Multiple doses |          | 62.50/69.83  | 1.12/1.13       |
|               |            | Single dose  | 62.50/70.68 | 62.50/70.60  | 62.50/76.68     |
|               |            | Multiple doses |          | 1.13/1.13    | 1.23/1.23       |

1 The predicted AUC of tacrolimus alone; 2 the predicted AUC of tacrolimus after coadministration with inhibitor (unit, ng/mL·h); 3 AUC ratio (AUCR) between coadministration with inhibitor and without inhibitor.

3. Discussion

The combined use of tacrolimus and WZC led to increased blood concentrations of tacrolimus, with AUC changes ranging from 57% to 366% [28]. Similarly, SZB led to a 200% increase in bosutinib exposure [29], indicating the urgent clinical need to identify potential interactions when co-prescribing WZC. As multiple active ingredients of WZC inhibit CYP3A4 and CYP3A5, it is challenging to elucidate the contributions of individual components. Furthermore, the polymorphism of the CYP3A5 enzyme causes
With our previous findings on STA and SIA [17], we noticed much weaker interactions work demonstrated the inhibitory patterns of STA and SIA and integrated them into a AUC of the tacrolimus by 16% after multiple doses. These findings corroborated the results (K pooled HLMs to identify the inhibitory patterns. Our results found that the SZA only CYP3A5 *1/*3 consequently, the metabolic study was carried out on the genotyped HLMs (K CYP3A5 *3/*3 and CYP3A5 *3/*3) to examine the inhibitory effect of the SZA/SZB on the CYP3A4 and CYP3A5, respectively. The SZA only demonstrated an irreversible inhibitory pattern (Kf = 15.38 µM, k_inact = 0.024 min⁻¹, k_inact / Kf = 1.56 mL/min/µmol) on the CYP3A4; however, the SZB exhibited both RI and TDI patterns on the CYP3A4 (Kf = 2.03 µM, Kf = 0.69 µM, k_inact = 0.37 min⁻¹, k_inact / Kf = 536.2 mL/min/µmol) and the CYP3A5 (Kf = 2.18 µM, Kf = 0.5 µM, k_inact = 0.009 min⁻¹, k_inact / Kf = 18 mL/min/µmol). Our results confirmed the findings of prior studies, according to which SZB caused moderate-to-strong CYP3A inhibition both reversibly and irreversibly, while SZA exhibited weak potency via TDI [31,34]. Interestingly, we identified that the SZB had a stronger inhibitory activity on the CYP3A4 than on the CYP3A5. A significant potency drop was noted in the assay with the pooled HLMs compared to the HLM with the CYP3A5 *3/*3 genotype. This finding could be attributed to the higher affinity and lower potency of SZB on CYP3A5 resulting in the dilution of the inhibitory effect. In this case, CYP3A5 expressers are expected to display higher variability in their tacrolimus metabolic/plasma profiles due to SZB inhibition.

Even though SZA and SZB only account for a small proportion of WZCs, their high blood levels were occasionally observed after oral administration [35]. This disparity could be explained by increased bioavailability or mutual biotransformation internally, caused by the presence of other ingredients in the compounded products [36]. Obviously, it is challenging to perform an in vivo study to investigate the whole product, considering the unidentifiable pharmacokinetic and pharmacodynamic interactions among the active components. In addition to its cost-effectiveness, PBPK modeling is particularly helpful for integrating the pharmacokinetic properties of individual agents. Based on the actual blood concentrations, we set the virtual doses of the SZA and the SZB. At doses of 33.6 mg for SZA and 10.8 mg for SZB, our models display excellent fitness, with a fold error within 2.

Along with the established model for tacrolimus, we developed a PBPK–DDI model to investigate the impact of CYP3A5 genotypes on interactions with SZA or SZB. Interestingly, little influence was found on tacrolimus’ systemic exposure after a single dose of SZA regardless of CYP3A5 expression. In the CYP3A5 non-expressers, the SZA increased the AUC of the tacrolimus by 16% after multiple doses. These findings corroborated the results suggesting the weak TDI on the CYP3A4 mentioned above. On the other hand, single doses of SZB increased the AUC of the tacrolimus by 15% and 14% in the CYP3A5 expressers and non-expressers, respectively. This DDI was more potent in the multiple-dose settings.

It could be concluded that the SZB exhibited a more significant DDI in the CYP3A5 non-expressers, i.e., that the TDI on the CYP3A4 of the SZB contributed the most. Compared with our previous findings on STA and SIA [17], we noticed much weaker interactions between the SZA/SZB and the tacrolimus. It is worth mentioning that SZB contains a methylenedioxy moiety that is not present in SZA (Figure 1). A previous study suggested
an association between this functional group and irreversible inhibition on CYP450 enzymes [37]; this could explain why the SZB displayed stronger inhibitory potency. However, further investigation is required to elucidate the structure–inhibitory-activity relationship.

The present study has some limitations. Firstly, transplantation patients were not included in our population database, causing potential bias in the simulation. Secondly, our models were restricted to examining the interaction between individual compounds and not the whole WZC; however, the latter is more clinically relevant. Such limitations could be overcome by further explorations and implementations of integrated PBPK models with different individual components. The findings from our study will contribute to the DDI information of SZA and SZB and, hopefully, facilitate future research on combining different components into one model.

It is beyond doubt that personalized medicine is the future direction of disease management. The integration of pharmacogenetics to design dosing regimens definitely leads to better pharmacotherapeutic outcomes; however, the pharmacogenomic information on Chinese traditional medicine preparations is sparse. Our study provides a practical strategy to evaluate the impact of CYP3A5 polymorphism on DDI caused by critical perpetrator compounds present in WZC. Elucidation of the influence of CYP3A5 polymorphism on tacrolimus metabolism allows more accurate DDI prediction using the PBPK modeling approach.

4. Materials and Methods
4.1. Chemicals and Reagents
Schizandrol A (purity ≥ 98%, lot: 58546–56-8) and Schizandrol B (purity ≥ 98%, lot: 58546–55-7) were purchased from PUSH Bio-Technology Co., Ltd. (Chengdu, China). CYP3cide (PF-4981517, lot: ECD192–1-PFZ), 6β-hydroxytestosterone (purity ≥ 98%, lot: A0277795) and nicotinamide adenine dinucleotide phosphate (NADPH, lot: LA50Q51) were obtained from J&K Technology Co., Ltd. (Beijing, China). Tacrolimus (purity ≥ 99.0%, lot: 050701130614) and testosterone (purity ≥ 99.0%, lot: L1415024) were obtained from Aladdin Biochemical Technology Co., Ltd. (Shanghai, China). Ascomycin (purity ≥ 99.0%, lot: D1202AS) and prednisolone (purity ≥ 98%, lot: J0402AS) were from Dalian Meilun Bio-Technology Co., Ltd. (Dalian, China). Pooled human-liver microsomes (HLMs, lot: 4133007) from 22 donors were obtained from BD Biosciences Co., Ltd. (New York, NY, USA). CYP3A5 *1/*3 HLMs (lot: 0710232) and CYP3A5 *3/*3 HLMs (lot: 0710253) were purchased from Transsheep Co., Ltd. (Shanghai, China). All other reagents and solvents were from standard chemical suppliers and of analytical grade.

4.2. Analytical Instruments
All metabolic samples were analyzed by liquid chromatography–tandem mass spectrometry (LC-MS/MS). The details of bioanalytical protocol can be found in our previous publications [14,17] and Supplementary Data (Table S1).

4.3. CYP450 Enzyme-Inhibition Assay Protocols
4.3.1. IC50 Shift Assay
IC50 shift assay was performed to discriminate reversible or irreversible inhibition caused by SZA and SZB. Pooled HLMs were used in this assay to determine the IC50 shift and identify time-dependent inhibition. The experiment was divided into two groups, depending on preincubation status. The basic incubation mixture with a total volume of 200 µL contained potassium phosphate buffer solution (PBS, 0.1 M, pH = 7.4), SZA (0, 20, 30, 40, 50, 60, 70, 80, 90, or 100 µM) or SZB (0, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 10, or 20 µM), MgCl2 (3 mM), NADPH (1 mM), testosterone (200 µM) and pooled HLMs (0.5 mg/mL).

In all samples, the final concentrations of organic solvents were not more than 1% (V/V). Schizandrol (A or B) was pre-incubated with the pooled HLMs and testosterone for 3 min at 3 °C. In the groups without 30-minute preincubation, the reaction was started upon the addition of NADPH and terminated by 200 µL of ice-cooled methanol containing 0.315 µM...
of prednisolone (internal standard). For other groups, the reaction mixture with SZA/SZB and HLMs was pre-incubated with NADPH at 37 °C for 30 min. Next, testosterone was added to initiate the reaction. The reaction was terminated with the same method. All experiments were carried out in triplicates.

4.3.2. Reversible Inhibition (RI) Assay

RI assay was used to measure the inhibitory constant (K_i) of SZA or SZB on CYP3A (pooled HLMs), CYP3A4 (CYP3A5 * 3/*3 HLMs) and CYP3A5 (CYP3A5 * 1/*3 HLMs + CYP3cide) [37]. The basic incubation mixture with a total volume of 100 µL consisted of PBS (0.1 M, pH = 7.4), SZA (0, 4, 8, or 16 µM)/SZB (0, 1, 2, or 4 µM), NADPH (1 mM), tacrolimus at different concentrations and HLMs (0.2 mg/mL). The final concentration of organic solvents did not exceed 1% (v/v). For the K_i value of CYP3A, tacrolimus (0.25, 0.5, 1, or 2 µM) was added to the reaction mixture, followed by 3-minute pre-warming. The reactions started upon the addition of NADPH and were terminated after 10 min by adding 200 µL of ice-cooled acetonitrile containing 0.1 µM of ascomycin (internal standard). Similar operations were applied in the experiments with genotyped HLMs, except that a pre-warmed mixture of CYP3cide (1.2 µM) and CYP3A5 * 1/*3 HLM (0.2 mg/mL) was pre-incubated with NADPH for 10 min before adding the tacrolimus (0.5, 1, 2, or 4 µM) and SZA/SZB. The reaction was also terminated with ice-cooled acetonitrile. All experiments were carried out in triplicates.

4.3.3. Time-Dependent Inhibition (TDI) Assay

A two-step protocol was followed to perform the general TDI assay. Firstly, SZA (0, 10, 16, 20, 25, or 32 µM)/SZB (0, 0.1, 0.2, 0.5, 1, or 2 µM) was incubated with pooled HLMs (0.5 mg/mL), PBS (0.1 M) and testosterone (200 µM) in a total volume of 200 µL, followed by 3-minute pre-warming at 37 °C in a shaking water bath. The reaction was initiated upon addition of NADPH (1 mM). At the designated time points (0, 5, 10, 20, or 30 min), an aliquot (20 µL) of the incubation mixture was transferred to a 180-microliter pre-warmed solution containing PBS (0.1 M), testosterone (200 µM) and NADPH (1 mM) for another 10-minute incubation. The reaction was stopped with ice-cooled acetonitrile containing prednisolone (0.315 µM). Similarly, the experiment for CYP3A4 followed the same steps described above, except for replacing pooled HLMs with CYP3A5 * 3/*3 HLMs with SZB at various concentrations (0, 0.5, 1, 2, 4, or 8 µM). For the CYP3A5 experiment, CYP3cide and CYP3A5 * 1/*3 HLMs were pre-warmed for 3 min before the reaction initiation. Various concentrations of SZA (0, 10, 20, 30, 40, or 50 µM) and SZB (0, 2, 4, 8, or 16 µM) were applied. All experiments were carried out in triplicates.

4.4. Data Analysis

4.4.1. IC_{50} Values and Shift

IC_{50} values of SZA and SZB were determined by nonlinear regression analyses using GraphPad Prism version 5.0.0 (GraphPad Software, La Jolla, CA, USA). The formation of 6β-hydroxytestosterone in a control group was used as a surrogate marker for remaining enzymes' activity. The formation rate was plotted against the logarithm concentration of the inhibitor (SZA or SZB). IC_{50} shift value was determined by Equation (2). A value of IC_{50} shift larger than 1.5 indicates time-dependent inhibition.

\[
\text{IC}_{50} \text{ shift} = \frac{\text{IC}_{50} \text{ without NADPH preincubation}}{\text{IC}_{50} \text{ with NADPH preincubation}}
\]

4.4.2. K_i Value

Dixon plots were used to determine the K_i value and the inhibitory type of SZA and SZB. Linear regression implemented in GraphPad Prism was plotted with the reciprocal value of metabolic reaction rate (1/v) against inhibitor concentration. The intersection of lines was used to calculate the K_i value.
4.4.3. $K_I$, $k_{inact}$ and $k_{obs}$ Values

The production rate of the $6\beta$-hydroxytestosterone was used to demonstrate the remaining enzyme activity, which was plotted logarithmically against the preincubation time as abscissa. Kinetic parameters of the TDI ($K_I$ and $k_{inact}$ refer to the inhibitor concentration causing half-maximal inactivation and the maximal inactivation rate constant, respectively) were determined with Equation (3). $k_{obs}$ refers to the observed inactivation rate of the affected enzyme, determined by the negative slope of the linear regression. $k_{inact}$ is calculated with the negative reciprocal value of the straight line at the $Y$-intercept, while the interception on $X$-axis represents $K_I$. [$I$] stands for the inhibitor concentration. A high ratio of $k_{inact}$ over $K_I$ indicates great inhibitory potency.

$$k_{obs} = \frac{k_{inact} \times [I]}{K_I + [I]}$$  \hspace{1cm} (3)

4.5.! Model Development

Parameters of the PBPK model are listed in Table 3. All physicochemical and in vitro pharmacokinetic parameters were obtained from the literature or predicted by Simcyp® Simulator (version 16, Certara, Sheffield, U.K.). The intrinsic clearance value of pooled HLMs and human tacrolimus PBPK model was retrieved from our previous publication [14]. The models for CYP3A5 expressers/non-expressers were built by modifying our established model with intrinsic clearance values of each CYP isoform [17,19]. With the inhibitory parameters acquired from our experiments, a DDI module was incorporated into the PBPK model of tacrolimus.

**Table 3. Input parameters of PBPK simulations.**

| Parameters                  | SZA Value | SZB Value | Reference               |
|-----------------------------|-----------|-----------|-------------------------|
| Molecular weight (g/mol)    | 432.52    | 416.47    | -                       |
| Ionization pattern          | Neutral   | Neutral   | -                       |
| $\log_{\text{pKw}}$        | 3.390     | 3.380     | Predicted by ADMET Predictor$^{11}$ |
| $f_{u, \text{plasma}}$      | 0.083     | 0.084     | Predicted by Simcyp®    |
| $B/P$                       | 1.254     | 0.785     | Predicted by Simcyp®    |

**Absorption phase**

| Model | ADAM | - |
|-------|------|---|
| $f_a$ | 0.500 | 0.734 | Optimized using Simcyp® |
| $k_a$ | 0.218 | 0.437 | Optimized using Simcyp® |
| $P_{\text{eff, human}} (\times 10^{-4} \text{ cm/s})$ | 0.500 | 1.000 | Optimized using Simcyp® |

**Distribution phase**

| Model | Full PBPK |
|-------|-----------|
| $V_{ss}$ (L/kg) | 2.516 | 2.225 | Method 1$^{12}$ |
| $K_p$ scalar | 0.5 | 1 | Optimized using Simcyp® |

**Elimination phase**

| Model | Whole-Organ Metabolic Clearance |
Table 3. Cont.

| Parameters | SZA | SZB |
|------------|-----|-----|
| CL<sub>int,HLM</sub> (µL/min/mg) <sup>10</sup> | 50  | 4.5 | In-house data |

<sup>1</sup> Log <sub>P</sub><sub>ow</sub>: the partition coefficient in oil and water; <sup>2</sup> <sub>f</sub><sub>u,plasma</sub>: unbound fraction in plasma; <sup>3</sup> <sub>B/P</sub>: blood to plasma ratio; <sup>4</sup> <sub>f</sub><sub>a</sub>: the fraction of drug dose entering the cellular space of the enterocytes; <sup>5</sup> <sub>k</sub><sub>i</sub>: the first-order absorption rate constant; <sup>6</sup> <sub>P<sub>eff,human</sub></sub>: the effective intestinal permeability in humans; <sup>7</sup> <sub>V</sub><sub>ss</sub>: the volume of distribution; <sup>8</sup> PSA: polar surface area; <sup>9</sup> <sub>K</sub><sub>p</sub>: scalar: scaling factor for tissue to plasma partition coefficient; <sup>10</sup> <sub>CL<sub>int,HLM</sub></sub>: intrinsic clearance in human liver microsomes; <sup>11</sup> ADMET Predictor Module in GastroPlus™ (version 9.0, Simulations Plus, Inc., Lancaster, CA, USA) was used for prediction.

5. Conclusions

In the present study, the inhibitory effects of SZA/SZB on CYP3 A4 and CYP3A5 were identified. Subsequently, the acquired information was successfully integrated into a PBPK model to quantify the DDI between the SZA/SZB and the tacrolimus, which was further complicated by the CYP3A5 genotype. The information obtained in this study improves our understanding of the DDI between WZC and tacrolimus. Clearly, PBPK modeling has emerged as a powerful approach to examine herb-involved DDI; special attention should be paid to the combined use of WZC and tacrolimus in clinical practice.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/ijms23094485/s1.

Author Contributions: Conceptualization, X.X.; methodology, Q.H., F.B. and Q.W.; software, F.B., Q.H. and X.Z. (Xiaomei Zhuang); validation, M.L. and Z.T.; formal analysis, J.L. and X.Z. (Xiao Zhu); writing—original draft preparation, Q.H. and F.B.; writing—review and editing, W.Y.M., X.Z. (Xiaozhu), Z.T., H.-S.L. and X.X.; visualization, Q.W.; supervision, X.X.; project administration, H.-S.L. and X.X.; funding acquisition, H.-S.L. and X.X. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the framework of the China–Korea international cooperation program managed by the National Natural Science Foundation of China and the National Research Foundation of Korea (No. 82011540409). The APC was funded by H.-S.L., with his personal resources.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article or Supplementary Material.

Acknowledgments: Certara UK (Simcyp Division) granted free access to the Simcyp<sup>®</sup> Simulators through an academic license.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Definition |
|--------------|-----------|
| ADME         | Absorption, distribution, metabolism and excretion |
| AUC          | Area under the curve |
| AUCR         | Area under the curve ratio |
| CPIC         | Clinical Pharmacogenetics Implementation Consortium |
| CYP450       | Cytochrome P450 |
| DDI          | Drug–drug interaction |
| FE           | Fold error |
| HPLC         | High-performance liquid chromatography |
| HLMIC<sub>50</sub> | Human-liver microsome50% inhibitory concentration |
| K<sub>i</sub> | Reversible inhibition constant |
| k<sub>obs</sub> | Observed inactivation rate of the affected enzyme |
| k<sub>inact</sub> | Maximum inactivation rate constant |
Inhibitor concentration causing half-maximal inactivation $K_I$
Mass spectrometry MS
Nicotinamide adenine dinucleotide phosphate NADPH
Physiologically based pharmacokinetic PBPK
Area under the curve ratio AUCR
Reversible inhibition RI
Schisantrad A SIA
Schisandherin A STA
Schizandrol A SZA
Schizandrol B SZB
Tacrolimus FK-506
Time-dependent inhibition TDI
Traditional Chinese medicine TCM
Wuzhi capsule WZC

References
1. Prescott, L.F. Pharmacokinetic Drug Interactions. *Lancet* **1969**, *294*, 1239–1243. [CrossRef]
2. Gonschior, A.; Christians, U.; Braun, F.; Winkler, M.; Linck, A.; Baumann, J.; Sewing, K. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). *Br. J. Clin. Pharmacol.* **1994**, *38*, 567–571. [CrossRef] [PubMed]
3. Riley, R.J.; Wilson, C.E. Cytochrome P450 time-dependent inhibition and induction: Advances in assays, risk analysis and modelling. *Expert Opin. Drug Metab. Toxicol.* **2015**, *11*, 557–572. [CrossRef] [PubMed]
4. Roslyn Thelingwani, C.M. Evaluation of Herbal Medicines: Value Addition to Traditional Medicines Through Metabolism, Pharmacokinetic and Safety Studies. *Curr. Drug Metab.* **2014**, *15*, 942–952. [CrossRef] [PubMed]
5. Ren, J.-L.; Zhang, A.-H.; Wang, X.-J. Traditional Chinese medicine for COVID-19 treatment. *Pharmacol. Res.* **2020**, *155*, 104734. [CrossRef]
6. Ashour, M.; Youssef, F.; Gad, H.; Wink, M. Inhibition of cytochrome P450 (CYP3A4) activity by extracts from 57 plants used in traditional chinese medicine (TCM). *Pharmacogn. Mag.* **2014**, *10*, 38–47. [CrossRef] [PubMed]
7. Xin, H.W.; Wu, X.; He, Y.; Yu, A.; Xiong, L.; Xiong, Y. Research Progress in Schisandra Chinensis Used in the Treatment of Drug-induced Liver Injury. *China Pharm.* **2018**, *28*, 477–480. (In Chinese)
8. Lohse, A.W.; Chazouilleres, O.; Dalekos, G.; Drenth, J.; Heneghan, M.; Hofer, H.; Lammert, F.; Lenzi, M. EASL Clinical Practice Guidelines: Autoimmune hepatitis. *J. Hepatol.* **2015**, *63*, 971–1004.
9. European Association for the Study of the Liver. Electronic address, e. e. e. EASL Clinical Practice Guidelines: Liver transplantation. *J. Hepatol.* **2016**, *64*, 433–485. [CrossRef]
10. Newsome, P.N.; Allison, M.E.; Andrews, P.A.; Auzinger, G.; Day, C.P.; Ferguson, J.W.; Henriksen, P.A.; Hubscher, S.G.; Manley, H.; Mickiernan, P.J.; et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. *Gut* **2012**, *61*, 484–500. [CrossRef]
11. Lampen, A.; Christians, U.W.E.; Guengerich, F.P.; Watkins, P.B.; Kolars, J.C.; Bader, A.; Gonschior, A.K.; Dralle, H.; Hackbarth, L.; Sewing, K.F. Metabolism of The Immunosuppressant Tacrolimus in the Small Intestine: Cytochrome P450, Drug Interactions and Interindividual Variability. *Drug Metab. Dispos.* **1995**, *23*, 1315–1324. [PubMed]
12. Chen, T.Q.; Lin, M.W.; Lu, J.W. Hyperkalemia induced by tacrolimus combined with Wuzhi-capsule following renal transplantation: One case report. *J. Clin. Rehabil. Tissue Eng. Res.* **2012**, *15*, 8341–8343. (In Chinese)
13. Xin, H.W.; Wu, X.; He, Y.; Yu, A.; Xiong, L.; Xiong, Y. Evaluation the effects and cost on the application of tacrolimus combination with Wuzhi—capsule in renal transplanted recipients. *Clin. J. Clin. Pharmacol.* **2011**, *27*, 295–298. (In Chinese)
14. Zhang, H.; Bu, F.; Li, L.; Jiao, Z.; Ma, G.; Cai, W.; Zhuang, X.; Lin, H.-S.; Shin, J.-G.; Xiang, X. Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling. *Basic Clin. Pharmacol. Toxicol.* **2018**, *122*, 331–340. [CrossRef]
15. Qin, X.L.; Bi, H.C.; Wang, X.D.; Li, J.L.; Wang, Y.; Xue, X.P.; Chen, X.; Wang, C.X.; Xu, L.J.; Wang, Y.T.; et al. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). *Int. J. Pharm.* **2010**, *389*, 114–121. [CrossRef]
16. Qin, X.L.; Chen, X.; Wang, Y.; Xue, X.P.; Wang, Y.; Li, J.L.; Wang, X.D.; Zhong, G.P.; Wang, C.X.; Yang, H.; et al. In Vivo to In Vitro Effects of Six Bioactive Lignans of Wuzhi Tablet (Schisandra Sphenanthera Extract) on the CYP3A/P-glycoprotein–Mediated Absorption and Metabolism of Tacrolimus. *Drug Metab. Dispos.* **2014**, *42*, 193–199. [CrossRef]
17. He, Q.; Bu, F.; Zhang, H.; Wang, Q.; Tang, Z.; Yuan, J.; Lin, H.-S.; Xiang, X. Investigation of the Impact of CYP3A5 Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling. *Pharmaceuticals* **2021**, *14*, 198. [CrossRef] [PubMed]
18. Birdwell, K.A.; Decker, B.; Barbarino, J.M.; Peterson, J.F.; Stein, C.M.; Sadee, W.; Wang, D.; Vinks, A.A.; He, Y.; Swen, J.J.; et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. *Clin. Pharmacol. Ther.* **2015**, *98*, 19–24. [CrossRef]
19. Dai, Y.; Hebert, M.F.; Isoherranen, N.; Davis, C.L.; Marsh, C.; Shen, D.D.; Thummel, K.E. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab. Dispos. 2006, 34, 836–847. [CrossRef]

20. Rojas, L.; Neumann, I.; Herrero, M.J.; Bosó, V.; Reig, J.; Poveda, J.L.; Megías, J.; Bea, S.; Alíno, S.F. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: A systematic review and meta-analysis of observational studies. Pharm. J. 2015, 15, 38–48. [CrossRef]

21. Hendijani, F.; Azarpira, N.; Kaviani, M. Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis. Clin. Transplant. 2018, 32, e13306. [CrossRef] [PubMed]

22. Gufford, B.; Barr, J.; González-Pérez, V.; Layton, M.; White, J.; Oberlies, N.; Paine, M. Quantitative prediction and clinical evaluation of an unexplored herb–drug interaction mechanism in healthy volunteers. CPT Pharmacomet. Syst. Pharmacol. 2015, 4, 701–710. [CrossRef] [PubMed]

23. Perdaems, N.; Blasco, H.; Vinson, C.; Chenel, M.; Whalley, S.; Cazade, F.; Bouzom, F. Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling. Clin. Pharmacokinet. 2010, 49, 239–258. [CrossRef] [PubMed]

24. Liu, H.; Yu, Y.; Guo, N.; Wang, X.; Han, B.; Xiang, X. Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib. Front. Pharm. 2021, 12, 780937. [CrossRef] [PubMed]

25. Zhang, Z.; Fu, S.; Wang, F.; Yang, C.; Wang, L.; Yang, M.; Zhang, W.; Zhong, W.; Zhuang, X. A PBPK Model of Ternary Cyclodextrin Complex of ST-246 Was Built to Achieve a Reasonable IV Infusion Regimen for the Treatment of Human Severe Smallpox. Front. Pharmacol. 2022, 13, 836356. [CrossRef]

26. Li, S.; Yu, Y.; Bian, X.; Yao, L.; Li, M.; Lou, Y.R.; Yuan, J.; Lin, H.S.; Liu, L.; Han, B.; et al. Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling. Arch. Toxicol. 2021, 95, 1683–1701. [CrossRef]

27. Wei, H.; Miao, H.; Yun, Y.; Li, J.; Qian, X.; Wu, R.; Chen, W. Validation of an LC–MS/MS Method for Quantitative Analysis of the 5 Bioactive Components of Wuzhi Capsule in Human Plasma Samples. Ther. Drug Monit. 2014, 36, 781–788. [CrossRef]

28. Fu, S.; Wang, L.; Zhu, Y.; Zhou, M.; Zhang, L. Effect of Wuzhi capsule on blood concentration of tacrolimus in renal graft recipients. Pharm. Care Res. 2009, 9, 275–278. (In Chinese)

29. Adiwidjaja, J.; Boddy, A.V.; Melachlan, A.J. Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: In vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. Br. J. Clin. Pharmacol. 2020, 86, 2080–2094. [CrossRef]

30. Jin, J.; Bi, H.; Hu, J.; Zhong, G.; Zhao, L.; Huang, Z.; Huang, M. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrin B in rats. Biopharm. Drug Dispos. 2010, 31, 264–268. [CrossRef]

31. Wan, C.K.; Tse, A.K.; Yu, Z.L.; Zhu, G.Y.; Wang, H.; Fong, D.W. Inhibition of cytochrome P450 3A4 activity by schisandrol A and schisandrin C in vivo. Arch. Toxicol. 2004, 78, 559–564. [PubMed]

32. Yuan, F.; Liang, X.; Chen, X.; Qin, X.; Tan, C.; Wang, L. CYP2C19 is involved in the effect of Wuzhi tablet (Schisandrae chinensis) and its constituents on the pharmacokinetics of intravenous voriconazole. Drug Metab. Dispos. 2013, 41, 1433–1441. [CrossRef] [PubMed]

33. Berry, L.M.; Zhao, Z.; Lin, M.-H.J. Dynamic Modeling of Cytochrome P450 Inhibition In Vitro: Impact of Inhibitor Depletion on IC50 Shift. Drug Metab. Dispos. 2013, 41, 1686–1697. [CrossRef]

34. Zhai, J.; Zhang, F.; Gao, S.; Chen, L.; Feng, G.; Yin, J.; Chen, W. Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats. Pharmacol. Ther. 2014, 49, 31–48. [CrossRef] [PubMed]

35. Wei, H.; Tao, X.; Di, P.; Yang, Y.; Li, J.; Qian, X.; Feng, J.; Chen, W. Effects of Traditional Chinese Medicine Wuzhi Capsule on Pharmacokinetics of Tacrolimus in Rats. Drug Metab. Dispos. 2013, 41, 1398–1403. [CrossRef]

36. Wu, H.; Zhu, Z.; Zhang, G.; Zhao, L.; Zhang, H.; Zhu, D.; Chai, Y. Comparative pharmacokinetic study of paenoflorin after oral administration of pure paenoflorin, extract of Cortex Moutan and Shuang-Dan prescription to rats. J. Ethnopharmacol. 2009, 129, 444–449. [CrossRef]

37. Walsky, R.L.; Obach, R.S.; Hyland, R.; Kang, P.; Zhou, S.; West, M.; Geoghegan, K.F.; Helal, C.J.; Walker, G.S.; Goosen, T.C.; et al. Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs. Drug Metab. Dispos. 2012, 40, 1686–1697. [CrossRef]

38. Poulin, P.; Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 2002, 91, 129–156. [CrossRef]

39. Berezhkovskiy, L.M. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J. Pharm. Sci. 2004, 93, 1628–1640. [CrossRef]